A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

NCT00821249 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma
Plasma Cell Leukemia

Interventions

DRUG: ARRY-520, KSP(Eg5) inhibitor; intravenous
DRUG: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
DRUG: Dexamethasone, steroid; oral

Sponsor

Pfizer